LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Update of the human parvovirus B19 biology.

    Servant-Delmas, A / Morinet, F

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine

    2016  Volume 23, Issue 1, Page(s) 5–12

    Abstract: Since its discovery, the human parvovirus B19 (B19V) has been associated with many clinical ... a new human parvovirus (PARV4) has been discovered. The consequences on blood transfusion of this blood ...

    Abstract Since its discovery, the human parvovirus B19 (B19V) has been associated with many clinical situations in addition to the prototype clinical manifestations, i.e. erythema infectiosum and erythroblastopenia crisis. The clinical significance of the viral B19V DNA persistence in sera after acute infection remains largely unknown. Such data may constitute a new clinical entity and is discussed in this manuscript. In 2002, despite the genetic diversity among B19V viruses has been reported to be very low, the description of markedly distinct sequences showed a new organization into three genotypes. The most recent common ancestor for B19V genotypes was estimated at early 1800s. B19V replication is enhanced by hypoxia and this might to explain the high viral load detected by quantitative PCR in the sera of infected patients. The minimum infectious dose necessary to transmit B19V infection by the transfusion of labile blood products remains unclear. At the opposite, the US Food and Drug Administration proposed a limit of 10(4)IU/mL of viral DNA in plasma pools used for the production of plasma derivatives. Recently, a new human parvovirus (PARV4) has been discovered. The consequences on blood transfusion of this blood-borne agent and its pathogenicity are still unknown.
    MeSH term(s) Blood Safety ; Cell Hypoxia ; DNA, Viral/analysis ; Genetic Variation ; Genotype ; Humans ; Parvoviridae Infections/prevention & control ; Parvoviridae Infections/transmission ; Parvoviridae Infections/virology ; Parvovirus B19, Human/classification ; Parvovirus B19, Human/genetics ; Parvovirus B19, Human/isolation & purification ; Parvovirus B19, Human/physiology ; Transfusion Reaction ; Viremia/prevention & control ; Viremia/transmission ; Viremia/virology ; Virus Replication
    Chemical Substances DNA, Viral
    Language English
    Publishing date 2016-02
    Publishing country France
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1204698-x
    ISSN 1953-8022 ; 1246-7820
    ISSN (online) 1953-8022
    ISSN 1246-7820
    DOI 10.1016/j.tracli.2015.11.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4097: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 308: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Virus et ATNC: le point sur la transmission par le sang.

    Barin, F

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine

    2000  Volume 7 Suppl 1, Page(s) 5s–10s

    Abstract: ... such as parvovirus B19 or hepatitis A virus (HAV), and/or the introduction of a nanofiltration step during ... by blood transfusion are human immunodeficiency virus (HIV) and hepatitis B and C viruses (respectively HBV, HCV ... 000 donations) were 0.17 for antibody to HIV, 0.08 for antibody to human T-cell leukemia virus (HTLV ...

    Title translation Viruses and unconventional transmissible agents: update on transmission via blood .
    Abstract The blood borne viruses must be separated into major and minor agents. Major viruses transmissible by blood transfusion are human immunodeficiency virus (HIV) and hepatitis B and C viruses (respectively HBV, HCV). The prevalence of virological markers in French blood donors has been continuously decreasing since the implementation of serological screening methods as soon as they were available. In 1998, the prevalences (per 10,000 donations) were 0.17 for antibody to HIV, 0.08 for antibody to human T-cell leukemia virus (HTLV), 2.23 for hepatitis B surface antigen (HBs Ag) and 2.52 for antibody to HCV. The values are, of course, higher in new donors when compared to regular donors: approximately five-fold for HIV, 50-fold for HCV and 300-fold for HBs Ag. The remaining major questions concern the residual risk due to infectious donations which could escape the preventive measures. It seems evident that the major risk is imputable mainly to donations collected during the window period. During the 1996-1998 period, the residual risk for HIV was 1 out of 1,350,000 donations, 0 for HTLV, 1 out of 375,000 for HCV, and 1 out of 220,000 for HBV. A few cases of "immunosilent" patients have been reported. They remain exceptional. The first data collected after the implementation of nucleic acid technology (NAT) confirm the very low residual risk. The recent introduction of leukodepletion probably brought an important contribution to diminishing the risk of transmission of leucotropic viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesviruses-6, -7 and -8, and HTLV. If the purification process of plasma-derived medicinal products including inactivation procedures makes it possible to be confident with the elimination of infectivity due to enveloped viruses, the detection of nucleic acid sequences derived from naked viruses in plasma pools such as parvovirus B19 or hepatitis A virus (HAV), and/or the introduction of a nanofiltration step during the purification process, when possible, may greatly contribute to their safety. The emergence of a new form of the Creutzfeldt-Jakob disease (nvCJD) introduces a new series of questions about the safety of blood products that, although the risks appear limited, are not yet resolved.
    MeSH term(s) Biological Products/adverse effects ; Blood Donors ; France/epidemiology ; HIV Infections/prevention & control ; HIV Infections/transmission ; Hepatitis, Viral, Human/prevention & control ; Hepatitis, Viral, Human/transmission ; Herpesviridae Infections/prevention & control ; Herpesviridae Infections/transmission ; Humans ; Mass Screening ; Prion Diseases/epidemiology ; Prion Diseases/prevention & control ; Prion Diseases/transmission ; Risk Assessment ; Transfusion Reaction ; Viremia/diagnosis ; Viremia/prevention & control ; Viremia/transmission ; Virus Diseases/epidemiology ; Virus Diseases/prevention & control ; Virus Diseases/transmission
    Chemical Substances Biological Products
    Language French
    Publishing date 2000-06
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 1204698-x
    ISSN 1953-8022 ; 1246-7820
    ISSN (online) 1953-8022
    ISSN 1246-7820
    DOI 10.1016/s1246-7820(00)80009-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4097: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 308: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top